Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients

Metastatic Breast Cancer Clinical Trial

Official title:

A Single-Institutional Phase IIa Trial and A Multi-Institutional Phase IIb Trial of Apatinib in Metastatic Triple-Negative Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01176669
• Other study ID #: Fudan BR2010-03
• Status: Completed
• Phase: Phase 2
• First received: July 20, 2010
• Last updated: September 8, 2015
• Start date: June 2010
• Est. completion date: September 2014

Study information

• Verified date: September 2015
• Source: Fudan University
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The hypothesis of this clinical research study is to discover if the study drug apatinib can shrink or slow the growth of pretreated metastatic triple-negative breast cancer.

Description:

Apatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor (VEGFR), and its anti-angiogenesis effect has been viewed in preclinical tests. The investigators' phase I study has shown that the drug's toxicity is manageable and the maximum tolerable daily dose is 850 mg. The hypothesis of this clinical research study is to discover if the study drug apatinib can shrink or slow the growth of triple-negative breast cancer. The safety of apatinib will also be studied. Patients physical state, symptoms, changes in the size of the tumor, and laboratory findings obtained while on-study will help the research team decide if apatinib is safe and effective in pretreated metastatic triple-negative breast cancer patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: September 2014
• Est. primary completion date: June 2014
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• = 18 and = 70 years of age.

• ECOG performance status of 0-1.

• Women diagnosed with triple negative breast cancer (breast cancer is estrogen receptor negative (ER-), progesterone receptor negative (PgR-) and human epidermal growth factor receptor negative (HER2-). HER2- is defined as 0 or 1+ staining on immunohistochemistry or FISH/CISH negative for gene amplification.

• Metastatic breast cancer, confirmed by histological analysis.

• Have failed for at least one chemotherapy regimen, but at most three regimens(including adjuvant and neo-adjuvant setting).

• Duration from the last therapy (chemotherapy, radiotherapy, target therapy and operation) is more than 4 weeks (Duration for nitroso or mitomycin is 6 weeks).

• Have at least one extracranial measurable site of disease according to RECIST 1.1 criteria that has not been previously irradiated. If the patient has had previous radiation to the marker lesion(s), there must be evidence of disease progression since the radiation.

• Life expectancy of more than 3 months.

• If the patients have brain or meninges metastases, the lesions must have been controlled at least 8 weeks.

• Adequate hepatic, renal, heart, and hematologic functions (hemoglobin = 9.0g/dl, neutrophils = 1.5×10^9/L, platelets = 80×10^9/L , ALT = 2.5 x upper limit of normal (ULN), AST = 2.5 x ULN, serum bilirubin = 1.5 x ULN, serum creatine = 1.5 x ULN, creatinine clearance rate = 50ml/min, PT, APTT, TT, Fbg normal).

• Written informed consent prior to study specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time without prejudice.

Exclusion Criteria:

• Pregnant or lactating women.

• Less than 4 weeks from the last clinical trial.

• Have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as: Congestive heart failure: New York Heart Association Class III/IV, Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6 months of start of study drug, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease.

• Any factors that influence the usage of oral administration.

• Receiving the therapy of thrombolysis or anticoagulation.

• Unhealed wound or bone fracture.

• Urine protein =++ and confirmed >1.0 g by the 24h quantity.

• Previous or present history of pulmonary fibrosis,interstitial pneumonia,pneumoconiosis,radiation pneumonitis,drug-related pneumonitis or greatly-impaired pulmonary function.

• Disability of serious uncontrolled intercurrence infection.

• Abuse of alcohol or drugs.

• Have received prior treatment with a VEGFR, PDGFR or s-SRC TKI (Bevacizumab is permitted).

• History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Neoplasms
• Metastatic Breast Cancer
• Triple Negative Breast Neoplasms

Intervention

Drug:
• Apatinib
Apatinib was administratered at 750 mg/d in Phase IIa. The actual average dose intensity delivered was 525 mg/d due to toxicities. So, in Phase IIb, the starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.

Locations

Country	Name	City	State
China	Fudan University Cancer Hospital	Shanghai	Shanghai

Sponsors (2)

Lead Sponsor	Collaborator
Fudan University	Jiangsu HengRui Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	DCR(Disease control rate) for IIa		8 Weeks	Yes
Primary	PFS(Progression free survival) for IIb		8 Weeks	Yes
Secondary	PFS(Progression free survival) for IIa		8 Weeks	Yes
Secondary	OS (Overall survival)		8 Weeks	Yes
Secondary	ORR (Objective response rate)		8 Weeks	Yes
Secondary	Number of Participants with Adverse Events as a Measure of Safety and Tolerability		8 weeks	Yes
Secondary	QoL (Quality of life)		8 Weeks	Yes
Secondary	DCR(Disease control rate) for IIb		8 Weeks	Yes